These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26663264)

  • 1. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
    Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
    Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
    Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
    Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
    Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
    Pullarkat V; Aldoss I
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
    Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients.
    El Gammal MM; Owaidat HM; Rashed RA; Fatah RA; Samra MA
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e406-e413. PubMed ID: 31031147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
    Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
    Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.
    England JT; Saini L; Hogge D; Forrest D; Narayanan S; Power M; Nevill T; Kuchenbauer F; Hudoba M; Szkotak A; Brandwein J; Sanford D
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e427-e436. PubMed ID: 32201130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
    Jia JS; Yang SM; Wang J; Jiang H; Zhao T; Bao L; Shi HX; Lu J; Zhu HH; Lai YY; Jiang B; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):497-502. PubMed ID: 27431075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
    Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
    Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.
    Souto Filho JT; Loureiro MM; Pulcheri W; Morais JC; Nucci M; Portugal RD
    Diagn Pathol; 2015 Jul; 10():122. PubMed ID: 26205005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
    Dick FR; Burns CP; Weiner GJ; Heckman KD
    Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new prognostic stratification for patients with acute myeloid leukemia].
    Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
    Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
    Reagan JL; Sullivan MR; Winer ES; Lansigan F; Cardin MS; Castillo JJ
    Leuk Res; 2015 Aug; 39(8):812-7. PubMed ID: 26045177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.